Conexeu Completes Preclinical Study for Large-Volume Injectable, Eyes $2B Aesthetics Market
CNXU sits 33% above its 52-week low of $8.14 on elevated volume (3.0× avg).
Summary
Conexeu Sciences completed its 12-month P.R.O.O.F. preclinical study for CXU™, a thermosensitive collagen scaffold designed for large-volume body contouring. The platform targets an unclaimed injectable aesthetics market projected to reach $2 billion by 2030, driven by GLP-1 weight-loss drug adoption. CXU™ aims to restore volume in breasts, hips, and buttocks at a scale current fillers cannot achieve. The company, which went public on Nasdaq in May, now has preclinical evidence to support next-stage development. Peer-reviewed publication of detailed findings is pending.
At the time of this announcement, CNXU was trading at $10.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $276.7M. The 52-week trading range was $8.14 to $18.79. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.